Here is my recent interview with Thomas Sandgaard, Founder & CEO of @ZynexMedical aka $ZYXI

$ZYXI devices are used for pain management and recovery from injury/surgery -- hopefully instead of opioids

Watch here:
$ZYXI is the leader in electro-stimulation devices and they are 10x better than the crappy ones you buy on Amazon

$ZYXI devices have to be prescribed by a medical professional and given that my entire body hurts most days I'll be visiting my doctor very soon to get one.
$ZYXI is $80+ million in revenues in 2020 which was 76% YoY growth

$ZYXI also has 78% gross margins and is already profitable.

Thomas thinks $ZYXI can do $150M in 2021 and $300M in 2022

$ZYXI doubled the size of their sales force in 2020 and now have 500+ sales people.
Based on Thomas's $150M estimates this year it means $ZYXI is trading at around 3x sales with 80-90% revenue growth, 78% gross margins and $20M of EBITDA.

Sorry but $ZYXI should be a $40 stock based on these numbers which is my 12-month price target.
Even @fintrics likes $ZYXI although this PT is too conservative

Watch here:

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Jonah Lupton

Jonah Lupton Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @JonahLupton

5 Mar
Several people have asked me why I'm willing to pay 65x sales for $DMTK - it's a good question so here's my answer:

When you find a company like $DMTK that has the potential to grow revenues at 200% annually for the next 4+ years you don't sit back and wait for it to look cheap.
By the time $DMTK looks cheap it might be a $30+ billion company.

You have to adjust your mindset in you want to invest in these hypergrowth companies that have a smaller revenue base now but massive upside thanks to years of insane growth in the future.
Here are my revenue projections for $DMTK based on their current PLA product, Luminate, PLA+ and several other pipeline products:

2021 = $21M+
2022 = $70M+
2023 = $210M+
2024 = $550M+
2025 = $1,000M+

If $DMTK can get to $1+ billion in 2025 this will be a $25+ billion company
Read 7 tweets
5 Mar
Seems like two bad weeks in the markets brings out the worst in some people. It’s too bad b/c I love twitter but some people make it intolerable on certain days. It’s sad that these people have nothing better to do than create fake profiles for the purpose of harassing others.
I have always done my best to provide/create valuable content and help others become better investors.

I’m far from perfect. I don’t have a crystal ball. I make plenty of mistakes like everyone else.
All I can do is try my hardest to find great companies that can deliver strong returns for investors.

I have no idea what these companies will do in the short term. These are companies I want to own for many years.
Read 18 tweets
4 Mar
Solid numbers from $DMTK

Assay revenues up 214% YoY

$DMTK has a bright future. This is going to be a hypergrowth company for the next 3-4 years with current PLA product + Luminate + other genomics skin testing products in the pipeline.

$DMTK up 8% AH

businesswire.com/news/home/2021…
CEO just said that 85 million people have coverage for $DMTK smart patches through their insurance provider
CEO just said that Luminate is on track to be launched in 2021 Q4
Read 4 tweets
3 Mar
Just wrapped up a great interview with Thomas Sandgaard, Founder & CEO of $ZYXI -- @ZynexMedical

It's insane how undervalued $ZYXI is right now. The company has already given guidance for 2021 revenues around $150M and Thomas thinks they might be able to do $300M in 2022.
With a market cap under $500M this stock is trading at 3x 2021 sales and less than 2x 2022 sales.

Did I mention they have 78% gross margins and are already profitable.

They also have two new products coming to market later this year:
1) blood flow/loss monitor
2) sepsis monitor
It's worth mentioning that Thomas owns 46% of the company so he has more skin in the game than the average Founder or CEO -- I love this.

This interview will be sent to all Substack paid subscribers later today and then my free subscribers will get it later this week.
Read 4 tweets
3 Mar
One of the things we have to do as fund managers at Social Capital is submit a one-page writeup for any holdings that are 5% or greater.

I think this is a valuable exercise for all investors and I encourage others to do this for their personal portfolios.
I already submitted my writeups on $DMTK and $UPST

My conviction for both of these stocks is just as strong today as it was the first day I started buying them. In many ways it's even stronger now.

$UPST is growing at 60-70% with 84% gross margins 😍
If you're looking for a template, the sections in my writeup were:

- Stock Price / Market Cap / Enterprise Value

- Overview / Growth Strategy

- Valuation / Financials

- Catalysts / Upside

- Risks / Downside

- Position Sizing
Read 4 tweets
1 Mar
My recent Substack writeup is out and the company I profiled is @OwletBabyCare which is coming public via SPAC merger with $SBG

I believe @OwletBabyCare can grow revenues at 60-80% per year for the next 4+ years which takes them to $1+ billion in 2025.

jonahlupton.substack.com/p/sbg-owlet-ba…
I'll be interviewing @kgworkman, founder and CEO of @owletbabycare on Friday.

@OwletBabyCare is currently on the 3rd generation of their "smart sock" with a bunch of products in the pipeline including the pregnancy band and smart scale.
@OwletBabyCare wants to build the leading babytech company which includes the connected nursery and digital parenting platform.

@owletbabycare has a strong management team and the SPAC sponsor (Sandbridge) is the perfect group to take them public and help them scale.
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!